GS
TNGX icon

Gilead Sciences’s Tango Therapeutics TNGX Stock Holding History

Gilead Sciences’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,854,443
Closed -$40.8M – 9
2025
Q3 		$40.8M Hold
4,854,443
– – 2.28% 6
2025
Q2 		$24.9M Hold
4,854,443
– – 1.94% 5
2025
Q1 		$6.65M Hold
4,854,443
– – 0.56% 7
2024
Q4 		$15M Buy
+4,854,443
New +$22.5M 0.97% 8

Other funds holding TNGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gilead Sciences's TNGX Position: Q4 2025 in Review

Gilead Sciences sold out of Tango Therapeutics (TNGX) in Q4 2025, closing a stake of 4,854,443 shares — an estimated $40.8M sold.

Gilead Sciences first reported a position in TNGX in Q4 2024 and held it in 4 quarters. The position peaked at $40.8M in Q3 2025. 170 funds tracked by Wall St. Rank hold TNGX as of Q4 2025.

  • Gilead Sciences reported no remaining Tango Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Gilead Sciences sold 4,854,443 Tango Therapeutics shares in Q4 2025, an estimated $40.8M.
  • Gilead Sciences first reported a position in Tango Therapeutics in Q4 2024 and held it in 4 quarters.
  • Gilead Sciences's Tango Therapeutics position peaked at $40.8M in Q3 2025.
  • 170 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2025.

Based on Gilead Sciences's 13F filing for Q4 2025, filed 12 Feb 2026.